Nebraska Medicaid and GLP-1s
Look for Nebraska's position on these drugs where the state publishes policy and you will come away empty. Thirty provider bulletins across 2025 and 2026 do not name a single one of them. The record is in the minutes of the Medicaid drug utilization review board, which meets four times a year in a Lincoln hotel, revises the Wegovy authorization form, and writes to prescribers about what these drugs are being combined with.
What changed, and what the document says
What the board changed in January
Conditions applyA liver-disease indication was added to a form that already existed, which tells you the drug was already being authorized for something.
“Dianne Garside presented the Wegovy PA form. New indication criteria for MASH was added to the existing Wegovy PA form.”
Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026
The roll call
ContextFive members, five votes for, and a revision asked for from the floor before the vote was taken.
“A motion to approve the form with revisions to differentiate the correct dosage forms with their indications was made by Titchener and approved as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes.”
Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026
Who else was in the room
ContextThe manufacturer of the drug under discussion spoke during the public comment item, and the minutes record it.
“Novo-Nordisk representatives made comments regarding the presented Wegovy PA form.”
Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026
What the state is writing to prescribers about
Conditions applyNebraska's live GLP-1 project is a combination-safety letter campaign, and the board was given a response rate for it.
“Lee Stutzman provided updates on letters sent to prescribers regarding concomitant prescribing of GLP-1s and DPP4s.”
Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026
Where the criteria themselves are posted
ContextThe bulletin that announces drug list changes sends readers to a contractor's site for the criteria behind them. We could not verify that host by fetching, so nothing on this page is quoted from it.
“This provider bulletin is being issued to notify Medicaid providers of changes to the Nebraska Medicaid PDL, effective July 17, 2026.”
Nebraska Department of Health and Human Services, Division of Medicaid and Long-Term Care — June 17, 2026
The bill that would have settled it
ContextA 2024 bill would have required comprehensive obesity coverage. It was introduced with its own start date still a placeholder, and Nebraska has not enacted a requirement since.
“No later than XXX, the department shall provide comprehensive coverage for treatment of obesity for medicaid recipients with an indication for chronic weight management to include intensive behavioral therapy and anti-obesity medication as approved by the federal Food and Drug Administration.”
Legislature of Nebraska — Read first time January 04, 2024
What the state didn't publish
Nebraska has not announced a GLP-1 or weight-loss drug decision in any Medicaid provider bulletin it currently lists for 2025 or 2026.
We looked at 30 documents to say that — All 30 provider bulletins listed on the department's own bulletin index for 2025 and 2026, downloaded and read in full on 2026-09-12, and scanned for GLP-1, Wegovy, Zepbound, Saxenda, semaglutide, tirzepatide, liraglutide, anti-obesity, weight loss and weight management..
The identical scan in the same run found "dental" in 6 of the 30 bulletins, "pharmacy" in 4, "Preferred Drug List" in 2 and "prior authorization" in 2 — so the ruler does find words when the words are there, and the zero above describes the bulletins rather than the scanner.
Checked September 2026 against Provider Bulletin 26-10 — Changes to the Nebraska Medicaid Preferred Drug List (PDL), Nebraska Department of Health and Human Services, Division of Medicaid and Long-Term Care.
Which of these companies serve Nebraska?
Of the 257 companies we grade, 25 publish a list of the states they are licensed in. We checked 229 more and found no such list on any page we read; 3 we have not checked either way.
19 of those lists name Nebraska: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, ZYP Medical, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.
A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.
Sources
Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.
- Nebraska Medicaid DUR Board Meeting — minutes — Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board. Meeting date printed in the heading of the minutes: Tuesday January 13th, 2026.
- Provider Bulletin 26-10 — Changes to the Nebraska Medicaid Preferred Drug List (PDL) — Nebraska Department of Health and Human Services, Division of Medicaid and Long-Term Care. Date line in the bulletin's own header block: June 17, 2026.
- Legislative Bill 907, One Hundred Eighth Legislature, Second Session — Legislature of Nebraska. Introduction line printed on the bill's first page: Read first time January 04, 2024.
Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.
If you're paying cash instead
None of the above changes what a telehealth seller charges you. None of the 3 rows below carries both a medication price and a monthly fee we could capture, so no figure here is a sum. Each cell says what its number covers and what we could not confirm, and every number was read on the seller's own page.
Mint Med, altRX and WePeptideRx pay us nothing — none of the 3 below does. The buttons run through our own redirect so we can count the click, and counting is all they do.
| Grade | Provider | What a month actually costs | The one thing that matters here | Go to the provider |
|---|---|---|---|---|
| AVerified | Mint Med | $86a month, medication onlyCompounded semaglutide, twelve months prepaidMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.The lowest of the 4 medication prices we captured here | Compounded semaglutide at $106 billed monthly and $86 prepaid for a year, from a seller whose own marketing undersells the deal it is offering. | See its prices at Mint Med (opens in a new tab)Pays us nothing |
| CCaveat | altRX | $89a month, medication onlycompounded glp-1, offer rateMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.The product page's only price. A banner above it dates the offer to midnight on September 5.The lowest of the 6 medication prices we captured here | Branded pens at published cash rates — $1,249 for tirzepatide, $1,579 for semaglutide — which is what an authorization form stands between a member and. | See its prices at altRX (opens in a new tab)Pays us nothing |
| CCaveat | WePeptideRx | $79a month, medication onlycompounded low dose naltrexoneMedication only. We captured no separate monthly charge on the pages we read, which is what we found rather than proof that nothing else is billed.The lowest of the 12 medication prices we captured here | Branded Wegovy at $399 beside compounded semaglutide at $189, so the drug the board keeps revising a form for carries two very different cash prices on one page. | See its prices at WePeptideRx (opens in a new tab)Pays us nothing |
Our grading method and how we verify a price explain what those letters mean and where these figures came from.